Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;70(2):e30059.
doi: 10.1002/pbc.30059. Epub 2022 Nov 17.

Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration

Hari K Narayan  1 , Karyn Sheline  1 , Victor Wong  1 , Dennis Kuo  1 , Sun Choo  1 , Janet Yoon  2 , Kasey Leger  3 , Shelby Kutty  4 , Michael Fradley  5 , Adriana Tremoulet  1 , Bonnie Ky  5 , Saro Armenian  2 , Avirup Guha  6   7
Affiliations

Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration

Hari K Narayan et al. Pediatr Blood Cancer. 2023 Feb.

Abstract

We sought to examine cardiovascular toxicities associated with tyrosine kinase inhibitors in pediatrics. We examined 1624 pediatric adverse events with imatinib, dasatinib, sorafenib, pazopanib, crizotinib, and ruxolitinib reported to the Food and Drug Administration between January 1, 2015, and August 14, 2020. There were 102 cardiovascular event reports. Hypertension was the most commonly reported cardiovascular event and was most frequently associated with sorafenib and pazopanib. The presence of infection increased the reporting odds of cardiovascular events overall and specifically cardiac arrest, heart failure, and hypertension. These data provide early insight into cardiovascular toxicities with tyrosine kinase inhibitor use in pediatrics.

Keywords: cardiotoxicity; hypertension; pediatric cancer; tyrosine kinase inhibitor.

PubMed Disclaimer

References

REFERENCES

    1. Shen S, Chen X, Cai J, et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020;6(3):358-366.
    1. Widemann BC, Kim A, Fox E, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012;18(21):6011-6022.
    1. Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the Children's Oncology Group Phase I Consortium. J Clin Oncol. 2011;29(7):839-844.
    1. Li J, Gu J. Cardiovascular toxicities with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of 77 randomized controlled trials. Clin Drug Investig. 2018;38(12):1109-1123.
    1. Kobat H, Elkonaissi I, Foreman E, et al. Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward? J Oncol Pharm Pract. 2022:10781552221077417. https://doi.org/10.1177/10781552221077417

Publication types

LinkOut - more resources